

# Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/TE1AF34D503EN.html>

Date: April 2018

Pages: 80

Price: US\$ 3,500.00 (Single User License)

ID: TE1AF34D503EN

## Abstracts

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2018

### SUMMARY

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol (vitamin A) in the plasma.

The diseases caused by mutations include amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis and carpal tunnel syndrome.

Transthyretin (ATTR or Prealbumin or TBPA or TTR) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 2, 1, 1, 3 and 6 respectively.

Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Cardiovascular which include indications Familial Amyloid Neuropathies, Amyloidosis, Amyloid Cardiomyopathy, Familial Amyloid Cardiomyopathy, Alzheimer's Disease, Cardiomyopathy and Neuropathy.

The latest report Transthyretin - Pipeline Review, H1 2018, outlays comprehensive

information on the Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Transthyretin (ATTR or Prealbumin or TBPA or TTR)

The report reviews Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics and enlists all their major and minor projects

The report assesses Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transthyretin (ATTR or Prealbumin or TBPA or TTR) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transthyretin (ATTR or Prealbumin or TBPA or TTR)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transthyretin (ATTR or Prealbumin or TBPA or TTR) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Overview

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Companies Involved in

Therapeutics Development

Alnylam Pharmaceuticals Inc

Arcturus Therapeutics Ltd

Ionis Pharmaceuticals Inc

Neurimmune Holding AG

Pfizer Inc

Prothena Corp Plc

Regeneron Pharmaceuticals Inc

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Drug Profiles

AG-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AKCEA-TTR-LRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALN-TTRsc02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxycycline hyclate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EDE-1307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

inotersen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LUNAR-TTR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-189 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Oligonucleotides to Inhibit Transthyretin for Amyloidosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

patisiran - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRX-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tafamidis meglumine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tolcapone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Dormant Products

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Discontinued Products

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Product Development Milestones

Featured News & Press Releases

Apr 03, 2018: Silence Therapeutics: Litigation Update (Portugal and US)

Mar 29, 2018: Pfizer Announces Positive Topline Results From Phase 3 ATTR-ACT Study Of Tafamidis In Patients With Transthyretin Cardiomyopathy

Mar 28, 2018: Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis

Mar 28, 2018: Alnylam Presents New data from the Phase 1 study of ALN-TTRsc02 at the 16th International Symposium on Amyloidosis

Mar 28, 2018: Proclara Biosciences Presents Preclinical Data Supporting the Development of GAIM-Based Therapies for Peripheral Amyloidoses at the 16th International Symposium on Amyloidosis

Mar 26, 2018: Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis

Mar 20, 2018: Eidos Therapeutics to Host Symposium on TTR Stabilization at the 16th International Symposium on Amyloidosis

Mar 14, 2018: Alnylam to Present Clinical Trial Data on Amyloidosis Drug Candidate ALN-TTRsc02 at the 16th International Symposium on Amyloidosis

Mar 14, 2018: Alnylam to Report New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis

Feb 27, 2018: Intellia Therapeutics Announces Publication in Cell Reports of Preclinical Data Demonstrating Effective CRISPR/Cas9 Genome Editing Using Lipid Nanoparticle (LNP) Delivery Technology

Feb 01, 2018: Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

Jan 25, 2018: Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis

Jan 08, 2018: Ionis Inotersen NDA Accepted for Priority Review by the FDA

Dec 18, 2017: Sanofi and Alnylam Submit Marketing Authorization Application to the EMA for Patisiran for the Treatment of Hereditary ATTR Amyloidosis

Dec 12, 2017: Alnylam Completes Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Patisiran for the Treatment of Hereditary ATTR

(hATTR) Amyloidosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018 (Contd.1), H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by Alnylam Pharmaceuticals Inc, H1 2018  
Pipeline by Arcturus Therapeutics Ltd, H1 2018  
Pipeline by Ionis Pharmaceuticals Inc, H1 2018  
Pipeline by Neurimmune Holding AG, H1 2018  
Pipeline by Pfizer Inc, H1 2018  
Pipeline by Prothena Corp Plc, H1 2018  
Pipeline by Regeneron Pharmaceuticals Inc, H1 2018  
Dormant Projects, H1 2018  
Discontinued Products, H1 2018



## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

### COMPANIES MENTIONED

Alynham Pharmaceuticals Inc

Arcturus Therapeutics Ltd

Ionis Pharmaceuticals Inc

Neurimmune Holding AG

Pfizer Inc

Prothena Corp Plc

Regeneron Pharmaceuticals Inc

## I would like to order

Product name: Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/TE1AF34D503EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/TE1AF34D503EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970